UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women's Hospital
UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women's Hospital |
| [23-October-2026] |
BRUSSELS and ATLANTA, Oct. 23, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company focused on severe diseases, today announced the establishment of the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women's Hospital, a founding member of the Mass General Brigham system. Named in honor of Emmanuel Janssen and his legacy at UCB, the chair recognizes a longstanding commitment to advancing science and improving patient care. Sebastian Schneeweiss, MD, ScD, has been named the chair's inaugural incumbent.
The gift creates a permanently endowed chair fund in the specialty of pharmacoepidemiology and pharmacoeconomics. UCB selected Brigham and Women's Hospital in recognition of the institution's leadership in pharmacoepidemiology and real-world evidence (RWE), and its work with both regulators and payers to establish RWE as a pivotal part of evidence generation. "We selected Brigham and Women's Hospital because of its leadership in pharmacoepidemiology and its ability to translate real-world evidence into insights that can inform decisions by regulators, payers, clinicians, and patients," said Emmanuel Caeymaex, Head of Patient Evidence at UCB. "This endowed chair reflects our commitment to advancing rigorous evidence generation and supporting research that can improve how medicines are evaluated and used in clinical practice." "I am deeply grateful to UCB Pharma for its generous support of pharmacoepidemiology research across our system," said Jose Florez, MD, PhD, Chair of the Department of Medicine at Mass General Brigham. "An endowed chair is among the highest honors we can bestow upon a physician-scientist, recognizing both extraordinary achievement and the promise of continued discovery. This investment by UCB Pharma will help us continue to progress in a field that is essential to improving how medicines are evaluated and used to benefit patients." "I am sincerely grateful to receive this extraordinary honor," said Sebastian Schneeweiss, MD, ScD, inaugural incumbent of the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines. "Through our research, we strive to generate rigorous evidence, guide better decisions, and improve care for patients. This chair will help advance that important work for years to come." A celebration honoring the establishment of the chair and its inaugural incumbent was held on Thursday, October 22, 2026, in the Stewart and Susan Satter Atrium of the Hale Building for Transformative Medicine at Brigham and Women's Hospital, 60 Fenwood Road, Boston. The program featured remarks from Dr. Florez; Robert Califf, MD, former Commissioner of the U.S. Food and Drug Administration; Jerry Avorn, MD, Founding Chief Emeritus of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital; Charles-Antoine Janssen, Director and Vice Chair of the UCB Board of Directors, Emmanuel Caeymaex on behalf of UCB; and Dr. Schneeweiss. About UCB in the U.S. About UCB For further information, contact UCB: U.S. Communications Forward looking statements Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB's information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
SOURCE UCB | ||
Company Codes: EuronextBrussels:UCB |
View original content to download multimedia:
